References
- Gallagher MJ Yilmaz T Cervantes-Castañeda RA Foster CS The characteristic features of optical coherence tomography in posterior uveitis Br J Ophthalmol 2007 91 1680 1685 17591668
- Brumm MV Nguyen QD Fluocinolone acetonide intravitreal sustained release device – a new addition to the armamentarium of uveitic management Int J Nanomedicine 2007 2 55 64 17722513
- Jabs DA Rosenbaum JT Foster CS Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel Am J Ophthalmol 2000 130 492 513 11024423
- Vavvas D Foster CS Immunomodulatory medications in uveitis Int Ophthalmol Clin 2004 44 187 203 15211185
- Jaffe GJ Martin D Callanan D Fluocinolone Acetonide Uveitis Study Group Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study Ophthalmology 2006 113 1020 1027 16690128
- Fluocinolone acetonide ophthalmic – Bausch & Lomb: fluocinolone acetonide Envision TD implant Drugs R D 2005 6 116 119 15777105
- Taban M Lowder CY Kaiser PK Outcome of fluocinolone acetonide implant (Retisert) reimplantation for chronic noninfectious posterior uveitis Retina 2008 28 9 1280 1288 18628725
- Lim LL Smith JR Rosenbaum JT Retisert Curr Opin Investig Drugs 2005 6 11 1159 1167
- Berger BB Mendoza W Sclerotomy closure for Retisert implant Retina 2013 33 2 436 438 23298955
- Taban M Lowder CY Ventura AA Scleral thickness following fluocinilone acetonide implant (retisert) Ocul Immunol Inflamm 2010 18 4 305 313 20482407